Filing Details
- Accession Number:
- 0001209191-19-024315
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-10 19:45:37
- Reporting Period:
- 2019-04-08
- Accepted Time:
- 2019-04-10 19:45:37
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1131324 | Genomic Health Inc | GHDX | Services-Medical Laboratories (8071) | 770552594 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1333482 | J Kimberly Popovits | 301 Penobscot Dr. Redwood City CA 94063 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-03-29 | 7,000 | $0.00 | 118,952 | No | 5 | G | Indirect | Held by the Popovits 2010 Trust |
| Common Stock | Disposition | 2019-04-08 | 7,536 | $66.72 | 111,416 | No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
| Common Stock | Disposition | 2019-04-08 | 2,364 | $67.55 | 109,052 | No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
| Common Stock | Disposition | 2019-04-08 | 100 | $68.31 | 108,952 | No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | G | Indirect | Held by the Popovits 2010 Trust |
| No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
| No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
| No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 12,298 | Indirect | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits |
| Common Stock | 36,168 | Direct |
Footnotes
- These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on December 10, 2018.
- Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- Represents weighted average sale price. Actual sale prices ranged from $66.29 to $67.25.
- Represents weighted average sale price. Actual sale prices ranged from $67.30 to $68.03.
- Represents actual sale price.
- Represents shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Billionaire Hedge Funds
